Related Experiment Videos
Electroconvulsive therapy in patients on anticoagulants
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|February 1, 1982
Summary
This study suggests a safe method for administering electroconvulsive therapy (ECT) to patients on anticoagulants. Switching to heparin allows temporary discontinuation before ECT, minimizing hemorrhage risk.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Electroconvulsive therapy (ECT) is an effective treatment for severe depression.
- The risk of central nervous system (CNS) bleeding with ECT in patients on anticoagulants remains unclear.
- Anticoagulant medications like coumarin derivatives are commonly used in patients with depression.
Observation:
- Two cases of depressed patients requiring ECT while on coumarin derivatives were analyzed.
- Patients were temporarily switched from coumarin derivatives to heparin for ECT administration.
- Heparin's short half-life enabled discontinuation 6-8 hours before ECT, restoring normal coagulation.
Findings:
- No CNS bleeding or other complications were observed in either patient during or after ECT.
- The modified anticoagulation protocol effectively managed bleeding risk during ECT.
- Coagulation function returned to near-normal levels prior to ECT stimulus administration.
Implications:
- This heparin bridging strategy appears to minimize the risk of hemorrhage associated with ECT in patients on anticoagulants.
- The findings support the safe use of ECT in patients requiring anticoagulation therapy.
- Further research may validate this approach for broader clinical application in psychiatric care.